Quel est le prix pour Nabriva Therapeutics plc (NBRV)

Le prix pour Nabriva Therapeutics plc (NBRV) est $0.63

Quelle est la capitalisation boursière pour Nabriva Therapeutics plc (NBRV)

La capitalisation boursière pour Nabriva Therapeutics plc (NBRV) est $284.20K

Nabriva Therapeutics plc (NBRV) Rendement du Dividende

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

Année	Rendement du dividende	Changez
Pas assez de données pour les dates fournies.

Année

Rendement du dividende

Changez

Pas assez de données pour les dates fournies.

Entreprise	Rendement du dividende	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.65%	BE

Entreprise

Rendement du dividende

Pays